×
About 703 results

ALLMedicine™ T Cell Lymphomas Center

Research & Reviews  349 results

Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell ...
https://doi.org/10.1172/JCI139675
The Journal of Clinical Investigation; Carras S, Chartoire D et. al.

May 27th, 2021 - Peripheral T-cell lymphomas (PTCLs) represent a significant unmet medical need with dismalclinical outcome. T-cell receptor (TCR) is emerging as a key driver of T lymphocytestransformation. However, the role of chronic TCR activation in lymphomage...

Novel therapies targeting cutaneous T cell lymphomas and their microenvironment.
https://doi.org/10.1053/j.seminhematol.2021.02.002
Seminars in Hematology; Reneau JC, Wilcox RA

Apr 28th, 2021 - Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas with a generally indolent course managed with topical, skin-directed therapies. A small subset, however, will progress to advanced stage disease necessitating systemic therapy for di...

Novel therapeutic approaches for cutaneous T cell lymphomas.
https://doi.org/10.1080/1744666X.2021.1919085
Expert Review of Clinical Immunology; Pavlidis A, Piperi C et. al.

Apr 23rd, 2021 - Introduction: Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin's lymphoma, characterized by malignant T cells infiltrating the skin. CTCL exhibits vast heterogeneity which complicates diagnosis and therapeutic strategies. Current CTCL treatm...

Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatm...
https://doi.org/10.1111/ijlh.13498
International Journal of Laboratory Hematology; Zhang W, Wang W et. al.

Mar 18th, 2021 - Next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) detection is a promising monitoring tool for lymphoid malignancies. Studies for T cell lymphoma are limited. We explored whether this technology is applicable to T cell lymphoma ...

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma.
https://doi.org/10.1080/14656566.2021.1882997
Expert Opinion on Pharmacotherapy; Wolska-Washer A, Smolewski P et. al.

Feb 1st, 2021 - Peripheral T cell lymphomas (PTCL) are a group of heterogenous hematologic malignancies derived from post-thymic T lymphocytes and mature NK cells. Conventional chemotherapy does not guarantee a good outcome. The article summarizes recent investig...

see more →

Clinicaltrials.gov  351 results

Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell ...
https://doi.org/10.1172/JCI139675
The Journal of Clinical Investigation; Carras S, Chartoire D et. al.

May 27th, 2021 - Peripheral T-cell lymphomas (PTCLs) represent a significant unmet medical need with dismalclinical outcome. T-cell receptor (TCR) is emerging as a key driver of T lymphocytestransformation. However, the role of chronic TCR activation in lymphomage...

Novel therapies targeting cutaneous T cell lymphomas and their microenvironment.
https://doi.org/10.1053/j.seminhematol.2021.02.002
Seminars in Hematology; Reneau JC, Wilcox RA

Apr 28th, 2021 - Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas with a generally indolent course managed with topical, skin-directed therapies. A small subset, however, will progress to advanced stage disease necessitating systemic therapy for di...

Novel therapeutic approaches for cutaneous T cell lymphomas.
https://doi.org/10.1080/1744666X.2021.1919085
Expert Review of Clinical Immunology; Pavlidis A, Piperi C et. al.

Apr 23rd, 2021 - Introduction: Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin's lymphoma, characterized by malignant T cells infiltrating the skin. CTCL exhibits vast heterogeneity which complicates diagnosis and therapeutic strategies. Current CTCL treatm...

Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatm...
https://doi.org/10.1111/ijlh.13498
International Journal of Laboratory Hematology; Zhang W, Wang W et. al.

Mar 18th, 2021 - Next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) detection is a promising monitoring tool for lymphoid malignancies. Studies for T cell lymphoma are limited. We explored whether this technology is applicable to T cell lymphoma ...

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma.
https://doi.org/10.1080/14656566.2021.1882997
Expert Opinion on Pharmacotherapy; Wolska-Washer A, Smolewski P et. al.

Feb 1st, 2021 - Peripheral T cell lymphomas (PTCL) are a group of heterogenous hematologic malignancies derived from post-thymic T lymphocytes and mature NK cells. Conventional chemotherapy does not guarantee a good outcome. The article summarizes recent investig...

see more →

News  3 results

HDAC/HMA combo shows ‘remarkable’ activity in PTCL
https://www.mdedge.com/hematology-oncology/article/206189/t-cell-lymphomas/hdac/hma-combo-shows-remarkable-activity-ptcl?channel=303
Neil Osterweil

Aug 9th, 2019 - LUGANO, SWITZERLAND – A combination of 5-azacytidine and romidepsin showed promising activity in patients with peripheral T cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL) and primary cutaneous follicular helper T-cell lymph.

Treatment of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
https://www.medscape.com/viewarticle/551357

Abstract and Introduction Abstract Cutaneous T cell lymphomas (CTCL) represent a heterogeneous group of T-cell malignancies that manifest primarily in the skin. By far the most common variant of CTCL is mycosis fungoides and its leukemic variant S...

see more →